Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress
Michael I. Dorrell, Edith Aguilar, Ruth Jacobson, Oscar Yanes, Ray Gariano, John Heckenlively, Eyal Banin, G. Anthony Ramirez, Mehdi Gasmi, Alan Bird, Gary Siuzdak, Martin Friedlander
Michael I. Dorrell, Edith Aguilar, Ruth Jacobson, Oscar Yanes, Ray Gariano, John Heckenlively, Eyal Banin, G. Anthony Ramirez, Mehdi Gasmi, Alan Bird, Gary Siuzdak, Martin Friedlander
View: Text | PDF
Research Article Ophthalmology

Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress

  • Text
  • PDF
Abstract

In several disease states, abnormal growth of blood vessels is associated with local neuronal degeneration. This is particularly true in ocular diseases such as retinal angiomatous proliferation (RAP) and macular telangiectasia (MacTel), in which, despite the absence of large-scale leakage or hemorrhage, abnormal neovascularization (NV) is associated with local neuronal dysfunction. We describe here a retinal phenotype in mice with dysfunctional receptors for VLDL (Vldlr–/– mice) that closely resembles human retinal diseases in which abnormal intra- and subretinal NV is associated with photoreceptor cell death. Such cell death was evidenced by decreased cone and, to a lesser extent, rod opsin expression and abnormal electroretinograms. Cell death in the region of intraretinal vascular abnormalities was associated with an increased presence of markers associated with oxidative stress. Oral antioxidant supplementation protected against photoreceptor degeneration and preserved retinal function, despite the continued presence of abnormal intra- and subretinal vessels. What we believe to be novel, Müller cell–based, virally mediated delivery of neurotrophic compounds specifically to sites of NV was also neuroprotective. These observations demonstrate that neuronal loss secondary to NV can be prevented by the use of simple antioxidant dietary measures or cell-based delivery of neurotrophic factors, even when the underlying vascular phenotype is not altered.

Authors

Michael I. Dorrell, Edith Aguilar, Ruth Jacobson, Oscar Yanes, Ray Gariano, John Heckenlively, Eyal Banin, G. Anthony Ramirez, Mehdi Gasmi, Alan Bird, Gary Siuzdak, Martin Friedlander

×

Figure 2

Characterization of abnormal NV in the Vldlr–/– mouse retina.

Options: View larger image (or click on image) Download as PowerPoint
Characterization of abnormal NV in the Vldlr–/– mouse retina.
   
(A) Re...
(A) Retinal cross-section montage demonstrating multiple retinal abnormalities in the Vldlr–/– mouse retina at 3 months of age, including subretinal vessels (arrowheads), vascular leak (arrow), abnormal retinal morphology, abnormal neuronal layering in the ONL and INL, and loss of red/green (rd/gr) cone opsin staining. (B and C) Vascular leak was associated with a small subset of subretinal vessels, as demonstrated by extravasation of perfused 43-kDa fluorescein-labeled dextran. (D) Fenestrae within endothelial cells of the subretinal vessels were observed by electron microscopy. Inset shows a lower-magnification view, in which the boxed region defines the bounds of the higher-magnification view. (E) Punctate GFAP staining in retinal whole mounts demonstrated glial activation associated with abnormal NV in the Vldlr–/– mouse retinas. (F) This punctate staining represented Müller cells specifically activated around the abnormal intraretinal vessels. (G and H) The RPE formed multicellular layers that engulfed abnormal intraretinal vessels. (I) Electron microscopy demonstrated normal retinal morphology at P12, just prior to NV onset. (J) Montage of multiple electron microscopy images showing retinal damage spatially associated with abnormal NV in 2 separate regions, while intermittent retinal morphology between lesions remained mostly normal. Scale bars: 100 μm (A–C and E–G); 50 μm (H–J); 10 μm (D).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts